The Medicines and Healthcare products Regulatory Agency has approved the advanced melanoma medicine Opdualag (nivolumab-relatlimab) for patients from the age of twelve.
[Medicines and Healthcare Products Regulatory Agency]
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
Brought to you by
